ZURICH (Reuters) - Roche said patients with an aggressive type of breast cancer lived longer after taking an experimental "armed antibody" drug without the disease worsening than patients taking a combination of GlaxoSmithKline drug Tykerb and Roche's Xeloda. Though Roche said the Phase III data are not yet mature, the safety of the development drug -- dubbed T-DM1 -- is consistent with previous studies. Roche said it plans to submit the treatment to European and U.S
Read the original post:
Roche says development drug helps in breast cancer
Related External LinksDelhi - All India Meeting
No comments:
Post a Comment